These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 30158205)
1. IQOS: examination of Philip Morris International's claim of reduced exposure. St Helen G; Jacob Iii P; Nardone N; Benowitz NL Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205 [TBL] [Abstract][Full Text] [Related]
2. Revolution or redux? Assessing IQOS through a precursor product. Elias J; Dutra LM; St Helen G; Ling PM Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324 [TBL] [Abstract][Full Text] [Related]
3. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Glantz SA Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374 [TBL] [Abstract][Full Text] [Related]
4. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203 [TBL] [Abstract][Full Text] [Related]
5. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product. Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301 [TBL] [Abstract][Full Text] [Related]
6. Heated tobacco products likely appeal to adolescents and young adults. McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Nabavizadeh P; Liu J; Havel CM; Ibrahim S; Derakhshandeh R; Jacob Iii P; Springer ML Tob Control; 2018 Nov; 27(Suppl 1):s13-s19. PubMed ID: 30206183 [TBL] [Abstract][Full Text] [Related]
8. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products. McKelvey K; Baiocchi M; Halpern-Felsher B Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537 [TBL] [Abstract][Full Text] [Related]
9. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims. Popova L; Lempert LK; Glantz SA Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208 [TBL] [Abstract][Full Text] [Related]
10. IQOS labelling will mislead consumers. McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208 [TBL] [Abstract][Full Text] [Related]
11. Analysis of mainstream emissions, secondhand emissions and the environmental impact of IQOS waste: a systematic review on IQOS that accounts for data source. El-Kaassamani M; Yen M; Talih S; El-Hellani A Tob Control; 2022 May; ():. PubMed ID: 35568394 [TBL] [Abstract][Full Text] [Related]
12. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model. Lempert LK; Bialous S; Glantz S Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155 [TBL] [Abstract][Full Text] [Related]
13. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups. Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Tobacco Heating System 2.2. Part 3: Influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating System 2.2 aerosol. Schaller JP; Pijnenburg JPM; Ajithkumar A; Tricker AR Regul Toxicol Pharmacol; 2016 Nov; 81 Suppl 2():S48-S58. PubMed ID: 27793747 [TBL] [Abstract][Full Text] [Related]
15. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product. Max WB; Sung HY; Lightwood J; Wang Y; Yao T Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170 [TBL] [Abstract][Full Text] [Related]
16. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis. Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887 [TBL] [Abstract][Full Text] [Related]
17. Should IQOS Emissions Be Considered as Smoke and Harmful to Health? A Review of the Chemical Evidence. Uguna CN; Snape CE ACS Omega; 2022 Jul; 7(26):22111-22124. PubMed ID: 35811880 [TBL] [Abstract][Full Text] [Related]
18. Comparison of 3R4F cigarette smoke and IQOS heated tobacco product aerosol emissions. Kärkelä T; Tapper U; Kajolinna T Environ Sci Pollut Res Int; 2022 Apr; 29(18):27051-27069. PubMed ID: 34935111 [TBL] [Abstract][Full Text] [Related]
19. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS. Robichaud MO; Puryear T; Cohen JE; Kennedy RD Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968 [TBL] [Abstract][Full Text] [Related]